Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02548962 · ClinicalTrials.gov registry record · Phase 1
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Pharmacyclics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02548962 is a Phase 1 study that was terminated before completion, run by Pharmacyclics. The registered enrollment target is 11 participants.
The verdict
NCT02548962, a Phase 1 study, was terminated before completion, sponsored by Pharmacyclics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma. Phase 2b is a randomized, double-blind, multicenter study of ibrutinib or placebo, in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
Interventions
- DRUG Placebo
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Ibrutinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-06-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02548962
The ClinicalTrials.gov registry entry for NCT02548962 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02548962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02548962 about?
NCT02548962 is a clinical study titled "Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma". Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma. Phase 2b is a randomized, double-blind, multicenter study of ibrutinib or placebo, in combination with pomalidomide and de...
What is the current status of trial NCT02548962?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-03. Estimated completion is 2018-06-13.
What interventions are being tested in trial NCT02548962?
The interventions under investigation include: Placebo (DRUG), Dexamethasone (DRUG), Pomalidomide (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT02548962?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.